Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
- Conditions
- Crohn's Disease
- Registration Number
- NCT00077779
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 854
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Clinical remission (CDAI<150). 56 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (43)
Gastroenterology Associates of Fairfield County
🇺🇸Bridgeport, Connecticut, United States
Clinical Research of West Florida, Inc.
🇺🇸Clearwater, Florida, United States
Mark Lamet, MD
🇺🇸Hollywood, Florida, United States
Washington University School
🇺🇸St. Louis, Missouri, United States
Long Island Clinical Research Assoc.
🇺🇸Great Neck, New York, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
The University of Chicago
🇺🇸Chicago, Illinois, United States
University Hospitals of Cleveland
🇺🇸Cleveland, Ohio, United States
Cal-West, Inc.
🇺🇸San Francisco, California, United States
V.A. Medical Center
🇺🇸Gainsville, Florida, United States
Indianapolis Gastroenterology Research Foundation
🇺🇸Indianapolis, Indiana, United States
Nashville Medical Research
🇺🇸Nashville, Tennessee, United States
Wisconsin Center for Advanced Research
🇺🇸Milwaukee, Wisconsin, United States
Thornton Hospital Reumatology Division
🇺🇸La Jolla, California, United States
Chevy Chase Clinical Research
🇺🇸Chevy Chase, Maryland, United States
Gastroenterology Consultants
🇺🇸Ormond Beach, Florida, United States
Altoona Center for Clinical Research
🇺🇸Duncansville, Pennsylvania, United States
Columbia Gastro Associates
🇺🇸Columbia, South Carolina, United States
Carolina Digestive Health Associates
🇺🇸Charlotte, North Carolina, United States
Wilmington Gastroenterology
🇺🇸Wilmington, North Carolina, United States
UCSF San Francisco General Hospital
🇺🇸San Francisco, California, United States
St. Vincent Hospital: Research Department
🇺🇸Indianapolis, Indiana, United States
Mayo Clinic Research
🇺🇸Rochester, Minnesota, United States
Daniel Present, MD
🇺🇸New York, New York, United States
Drug Research Services, Inc.
🇺🇸Metairie, Louisiana, United States
Westhills Gastroenterology
🇺🇸Portland, Oregon, United States
Gastrointestinal Specialists
🇺🇸Richmond, Virginia, United States
Washington University School of Medicine
🇺🇸St. Louis, Missouri, United States
Discovery Research Inteternational, LLC
🇺🇸Milwaukee, Wisconsin, United States
Gastroenterology Center of the Mid South
🇺🇸Memphis, Tennessee, United States
Glenn Gordon, MD
🇺🇸Mexico, Missouri, United States
Western States Clinical Research
🇺🇸Arvada, Colorado, United States
Northwest Gastroenterology
🇺🇸Arlington Heights, Illinois, United States
Capital Gastroenterology Consultants, P.A.
🇺🇸Silver Spring, Maryland, United States
Clinical Pharmacology Study Group
🇺🇸Worcester, Massachusetts, United States
Maryland Clinical Trials
🇺🇸Annapolis, Maryland, United States
NY Center for Clinical Research
🇺🇸Lake Success, New York, United States
Digestive Disease Associates of Rockland
🇺🇸Pomona, New York, United States
Charlotte Gastroenterology & Hepatology
🇺🇸Charlotte, North Carolina, United States
Le Bauer Research, P.A.
🇺🇸Greensboro, North Carolina, United States
Carolina Research Associates
🇺🇸Charlotte, North Carolina, United States
Gastroenterology & Hematology
🇺🇸Kansas City, Missouri, United States